Tag Archives: Cory Kasimov

Analysts Offer Insights on Healthcare Companies: Acorda Therapeutics (NASDAQ: ACOR), Zimmer Biomet Holdings (NYSE: ZBH) and Insulet (NASDAQ: PODD)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Acorda Therapeutics (ACOR – Research Report), Zimmer Biomet Holdings (ZBH – Research Report) and Insulet (PODD – Research Report). Acorda Therapeutics (ACOR) In

Ultragenyx Pharmaceutical (RARE) Gets a Buy Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Ultragenyx Pharmaceutical (RARE – Research Report) on February 13 and set a price target of $76.00. The company’s shares closed last Monday at $61.13. According to TipRanks.com, Kasimov is a

Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Dexcom (NASDAQ: DXCM)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report) and Dexcom (DXCM – Research Report). Incyte (INCY) J.P. Morgan analyst Cory Kasimov maintained a Buy rating on Incyte on

Analysts Offer Insights on Healthcare Companies: Seattle Genetics (NASDAQ: SGEN) and Acasti Pharma (NASDAQ: ACST)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seattle Genetics (SGEN – Research Report) and Acasti Pharma (ACST – Research Report) with bullish sentiments. Seattle Genetics (SGEN) In a report

J.P. Morgan Maintains Their Hold Rating on Biogen (BIIB)

In a report released yesterday, Cory Kasimov from J.P. Morgan maintained a Hold rating on Biogen (BIIB – Research Report). The company’s shares closed last Monday at $332.87. According to TipRanks.com, Kasimov is a 4-star analyst with an average return

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD) and Zimmer Biomet Holdings (NYSE: ZBH)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and Zimmer Biomet Holdings (ZBH – Research Report) with bullish sentiments. Gilead Sciences (GILD) In a